

Experience with Combination 2D/3D Breast Tomosynthesis vs FFDM in the Screening Environment

Destounis S, Murphy P, Seifert P, Somerville P, Paulis L, Cavanaugh D, Arieno A, Morgan R



Presented at RSNA 2012, LL-BRS-MO3C Breast Imaging Afternoon CME Posters

For the complete abstract, please visit: http://rsna2012.rsna.org/search/event_display.cfm?em_id=12023526

OBJECTIVE

To review experience with patients undergoing screening mammography imaged with combination 2D/3D breast tomosynthesis or full field digital mammography (FFDM).

MATERIALS AND METHODS

The study cohort comprised of 527 patients that opted for 2D/3D breast tomosynthesis and a randomly selected sample group of 527 patients that were screened with FFDM from the time period of June 2011 to December 2011. Recall rates, personal history, breast densities and family history was compared between the two modalities.

FINDINGS

Average age for both the modalities was 59 years

| | Personal history reported in | Personal and family history | Positive family history | Dense breasts | # of Biopsies | Findings |
|-------|------------------------------|-----------------------------|-------------------------|---------------|---------------|-----------------------|
| 2D/3D | 31 | 29 | 280 | 62% | 7 | 4 benign, 3 malignant |
| FFDM | 19 | 6 | 196 | 54% | 3 | All benign |

CONCLUSION

The 2D/3D breast tomosynthesis group showed significantly lower recall rates despite increased risk factors compared to the FFDM group, with additional cancers found.



The Women's Health Company

MISC-02303 © 2012 Hologic, Inc. All rights reserved.

Hologic, Selenia and Dimensions are trademarks or registered trademarks of Hologic and/or Hologic subsidiaries in the United States and/or other countries. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of Hologic. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.